Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 2,
  • 3,
  • 3,
  • 3,
  • 3 and
  • 1Email author
BMC Cancer201616:8

https://doi.org/10.1186/s12885-015-2046-7

  • Received: 21 December 2015
  • Accepted: 21 December 2015
  • Published:

The original article was published in BMC Cancer 2015 15:941

Unfortunately, the original version of this article [1] contained a mistake. The word ‘survivin’ in the title was incorrectly included as ‘surviving’. The title has been corrected above and in the original article.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L’Aquila, L’Aquila, Italy
(2)
Pathology Division, San, Salvatore Hospital, L’Aquila, Italy
(3)
Karyopharm Therapeutics, Newton, MA, USA

Reference

  1. Gravina G, Mancini A, Sanita P, Vitale F, Marampon F, Ventura L. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. BMC Cancer. 2015;15:941.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© Gravina et al. 2016

Advertisement